近段时间，事关基孔肯雅热病毒在我国本土肆虐。 这个消息一经发布之后，导致全球资本市场出现剧变。 甚至出现了由"高利率利差"驱动的资本收割正在新兴市场蔓延。 就在这个时候，中国广东省顺德爆发基孔肯雅热病毒。 而美国却提前五个月就批准研发疫苗。 此次始作俑者居然是所谓的蚊子，而且还没有"特效药"。 事实上，这一切都是美国人干的。 毕竟，美国在基孔肯雅热爆发前，就已经提前研发出疫苗。 再加上美联储此前宣布，将基准利率维持在4.25%至4.5%区间不变。 这是今年以来，美联储连续五次在议息会议之后，宣布基准利率不变。 结果美联储选择按兵不动。 相反，美联储宣布维持现状之后，国际和国内期货市 这就可以视为，美联储拒绝降息，外加生物的双重"绞杀"，也让中美贸易朝着另外一个方向发展。 这件事需要从美联储投下"巨型炸弹"开始说起。 第一，在美联储宣布维持利率之前，主流市场的观点普遍认为，美联储会在无法承受的高利率面前，选 择快速降息。 ...

Company Overview - Valneva SE Sponsored ADR (VALN) shares increased by 17.4% to $7.32 in the last trading session, with a notable trading volume that exceeded the average [1] - The stock has gained 11.3% over the past four weeks, indicating a positive trend [1] Market Sentiment - The rise in VALN shares is attributed to positive market sentiment driven by recent regulatory successes and strong momentum in the biotech sector [2] - Investor confidence was bolstered by the European Medicines Agency (EMA) lifting age-based restrictions on Valneva's chikungunya vaccine, reflecting increasing regulatory support [2] Financial Expectations - Valneva is projected to report a quarterly loss of $0.27 per share, which is a year-over-year improvement of 27% [3] - Expected revenues for the upcoming quarter are $55.89 million, representing a 36.4% increase compared to the same quarter last year [3] Earnings Estimates - The consensus EPS estimate for Valneva has remained unchanged over the last 30 days, suggesting stability in earnings expectations [4] - The stock's price typically does not continue to rise without trends in earnings estimate revisions, indicating the importance of monitoring future earnings updates [4] Industry Context - Valneva is categorized within the Zacks Medical - Products industry, which includes other companies like GE HealthCare Technologies (GEHC) [5] - GEHC shares increased by 1% to $77.25, with a 6.3% return over the past month, indicating a positive trend in the same industry [5] GE HealthCare Overview - GE HealthCare's consensus EPS estimate for the upcoming report is $0.91, reflecting a 9% decrease from the previous year [6] - GE HealthCare also holds a Zacks Rank of 3 (Hold), similar to Valneva [6]

Core Viewpoint - The FDA and CDC have recommended that individuals aged 60 and above pause the administration of the chikungunya vaccine [1] Group 1 - The recommendation affects a specific demographic, indicating potential implications for public health and vaccine distribution strategies [1]

金十数据5月6日讯，两名知情人士透露，美国卫生部长小罗伯特-肯尼迪的一名助手正在寻求有关上月 一个外部专家小组推荐的三种疫苗的更多信息。疾病控制和预防中心的咨询小组就使用单独的疫苗接种 提出了建议，这些被批准的疫苗有助于预防呼吸道合胞病毒、脑膜炎和基孔肯雅热。疾病预防控制中心 不需要采纳他们的建议，但如果采纳，这些建议就会成为医疗从业者遵循的指导方针。美国卫生与公众 服务部的记录显示，威廉·雷恩·阿彻三世博士（Dr. William "Reyn" Archer III）在小肯尼迪于2月接任 后，作为秘书办公室的顾问加入了监督疾病预防控制中心的卫生与公众服务部。阿彻在过去几年里一直 在社交媒体上批评疫苗。最近几天，阿彻就咨询委员会的建议向疾控中心提出了质疑，这是他在卫生与 公众服务部的职责之一。 美国卫生部长的助手质疑专家的疫苗接种建议 ...